Results 41 to 50 of about 152,115 (284)

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports

Medicina
Background and Objectives: Variceal bleeding (VB) is the most concerning condition that is difficult to treat after atezolizumab/bevacizumab in patients with advanced hepatocellular carcinoma (HCC).
Kyeong-Min Yeom, Young-Gi Song, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim   +4 more
doaj   +1 more source

Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. [PDF]

, 2013
BackgroundPreclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models.MethodsWe conducted a ...
Bastida, Christel, Falchook, Gerald S, Fu, Siqing, Hong, David S, Jiang, Yunfang, Kurzrock, Razelle, Morgan-Linnell, Sonia K, Naing, Aung, Piha-Paul, Sarina A, Tsimberidou, Apostolia M, Wheler, Jennifer J, Zinner, Ralph   +11 more
core   +2 more sources

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

Medicina, 2021
Chemoimmunotherapy has become the standard of care as the first-line treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). The bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective than a non-bevacizumab ...
Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Nozomi Tani, Izumi Sato, Mai Tanimura, Takayuki Nakano, Keiko Tanimura, Daishiro Kato, Takayuki Takeda   +9 more
doaj   +1 more source

Comparison of Intravitreal Bevacizumab Upload Followed by a Dexamethasone Implant versus Dexamethasone Implant Monotherapy for Retinal Vein Occlusion with Macular Edema [PDF]

, 2012
Purpose: To compare the efficacy and safety of three intravitreal bevacizumab upload injections followed by a dexamethasone implant versus dexamethasone implant monotherapy in eyes with macular edema due to retinal vein occlusion.
Haritoglou, Christos, Kampik, Anselm, Kook, Daniel, Mayer, Wolfgang J., Remy, Matthias, Reznicek, Lukas, Ulbig, Michael, Wolf, Armin   +7 more
core   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Efficacy and Safety of Bevacizumab Biosimilar (Encoda) Compared With Reference Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer: A Multicenter, Real-World Study

Clinical Medicine Insights: Oncology
Background: The bevacizumab biosimilar (Encoda), which was approved by the National Medical Products Administration (NMPA) in China in 2019, is a biosimilar of bevacizumab.
Han Shan, Mengmeng Wang, Shuohan Huang, Hongyue Liu, Jiyong Liu, Qiong Du   +5 more
doaj   +1 more source

Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study

BMC Cancer, 2011
Background We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment. Methods We analyzed patient surveys and medical records for a population-based cohort with metastatic colorectal cancer ...
Fouad Mona N, Weeks Jane C, Zullig Leah L, Kolimaga Jane T, Schrag Deborah, Abbott David H, Grambow Steven C, Malin Jennifer L, Zafar S Yousuf, Ayanian John Z, Wallace Robert, Kahn Katherine L, Ganz Patricia A, Catalano Paul, West Dee W, Provenzale Dawn   +15 more
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review

Frontiers in Oncology
In clinical use, bevacizumab has improved the overall survival (OS) and progression-free survival (PFS) of malignant solid tumors, and the safe use of bevacizumab has gradually become the mainstream direction of clinical, nursing and pharmaceutical ...
Ke Chen, Boyang Jiang, Boyang Jiang, Huiping Yan, Huiping Yan, Liu Yang, Liu Yang, Zheling Chen, Zheling Chen   +8 more
doaj   +1 more source